Acute heart failure with accompanying chronic obstructive pulmonary disease Should we focus on beta blockers?


Ege M. R., Guray U., Guray Y., Yilmaz M. B., Yucel O., Zorlu A., ...Daha Fazla

HERZ, cilt.37, sa.7, ss.796-800, 2012 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 7
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s00059-012-3641-x
  • Dergi Adı: HERZ
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.796-800
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Background. Acute heart failure (AHF) with systolic dysfunction is associated with increased morbidity and mortality, and optimal therapy is not well established, despite the findings of evidence-based medicine. Beta blockers provide a mortality and morbidity benefit in patients with chronic systolic HF, and are currently indicated in all stages of patients with systolic HF. We evaluated therapies before discharge, in particular beta blockers, in patients hospitalized with AHF with and without accompanying chronic obstructive pulmonary disease (COPD).